SAFETY OF TRALOKINUMAB IN PAEDIATRIC PATIENTS AGED 12-17 WITH MODERATE-TO-SEVERE AROPIC DERMATITIS: RESULTS FROM THE PHASE 3 ECZTRA 6 TRIAL

被引：0

作者：

Wollenberg, Andreas ^{[1
,2
]}

Cork, Michael J. ^{[3
,4
]}

Flohr, Carsten ^{[5
,6
]}

Bewley, Anthony ^{[7
]}

Blauvelt, Andrew ^{[8
]}

Hong-H, Chih-Ho ^{[9
]}

Imafuku, Shinichi ^{[10
]}

Schuttelaar, Marie-Louise Anna ^{[11
]}

Simpson, Eric ^{[12
]}

Soong, Weily ^{[13
]}

Amoudruz, Petra ^{[14
]}

Lophaven, Katja ^{[14
]}

Kurbasic, Azra ^{[14
]}

Soldbro, Lise ^{[14
]}

Vest, Natacha ^{[14
]}

Paller, Amy ^{[15
]}

机构：

[1] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergy, Munich, Germany

[2] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dept Dermatol, Brussels, Belgium

[3] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield Dermatol Res, Sheffield, S Yorkshire, England

[4] Sheffield Teaching Hosp, NIHR Clin Res Facil, Sheffield, S Yorkshire, England

[5] Guys St Thomas NHS Fdn Trust, St Johns Inst Dermatol, Dept Paediattol, St John, NF, Canada

[6] Kings Coll London, London, England

[7] Barts Hlth NHS Trust, London, England

[8] Oregon Med Res Ctr, Portland, OR USA

[9] Univ British Columbia, Vancouver, BC, Canada

[10] Fukuoka Univ, Fukuoka, Japan

[11] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands

[12] Oregon Hlth & Sci Univ, Portland, OR USA

[13] Allervie Hlth Alabama Allergy & Asthma Ctr, Birmingham, AL USA

[14] LEO Pharma AS, Ballerup, Denmark

[15] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P067

引用

页码：58 / 58

页数：1

共 50 条

[11] Tralokinumab provides progressive and sustained efficacy in adolescents with moderate-to-severe atopic dermatitis: a post-hoc analysis of the ECZTRA 6 trial
Simpson, Eric L.
Wollenberg, Andreas
Kurbasic, Azra
Tindberg, Ann-Marie
Soldbro, Lise
Paller, Amy S.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[12] Efficacyand Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial (vol 159, pg 596, 2023)
Shin, L.
Kole, L. C. S.
Peebles, J. K.
[J]. JAMA DERMATOLOGY, 2023, 159 (06) : 673 - 673
[13] Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial
Silverberg, J. I.
Toth, D.
Bieber, T.
Alexis, A. F.
Elewski, B. E.
Pink, A. E.
Hijnen, D.
Jensen, T. N.
Bang, B.
Olsen, C. K.
Kurbasic, A.
Weidinger, S.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 450 - 463
[14] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
Blauvelt, Andrew
Gooderham, Melinda
Bhatia, Neal
Langley, Richard G.
Schneider, Shannon
Zoidis, John
Kurbasic, Azra
Armstrong, April
Silverberg, Jonathan, I
[J]. DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2499 - 2516
[15] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
Andrew Blauvelt
Melinda Gooderham
Neal Bhatia
Richard G. Langley
Shannon Schneider
John Zoidis
Azra Kurbasic
April Armstrong
Jonathan I. Silverberg
[J]. Dermatology and Therapy, 2022, 12 : 2499 - 2516
[16] Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials
Wollenberg, A.
Beck, L. A.
Weller, M. Bruin
Simpson, E. L.
Imafuku, S.
Boguniewicz, M.
Zachariae, R.
Olsen, C. K.
Thyssen, J. P.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 453 - 465
[17] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
Wollenberg, A.
Blauvelt, A.
Guttman-Yassky, E.
Worm, M.
Lynde, C.
Lacour, J. -P.
Spelman, L.
Katoh, N.
Saeki, H.
Poulin, Y.
Lesiak, A.
Kircik, L.
Cho, S. H.
Herranz, P.
Cork, M. J.
Peris, K.
Steffensen, L. A.
Bang, B.
Kuznetsova, A.
Jensen, T. N.
osterdal, M. L.
Simpson, E. L.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 437 - 449
[18] Laboratory safety of dupilumab in paediatric patients aged ≥ 6 to < 12 years with severe atopic dermatitis: results from a phase III trial (LIBERTY AD PEDS)
Wollenberg, A.
Thaci, D.
Cork, M. J.
Arkwright, P. D.
Gooderham, M.
Sun, X.
Vakil, J.
Khokhar, F. A.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E122 - E123
[19] Early changes in patient-relevant endpoints in three tralokinumab pivotal phase III trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis
Silverberg, J. I.
Cork, M.
Wollenberg, A.
Katoh, N.
Steffensen, L. A.
Kurbasic, A.
Olsen, C. K.
Kuznetsova, A.
Osterdal, M. L.
Vilsboll, A. W.
Deleuran, M.
Simpson, E.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E64 - E64
[20] Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities
Paller, Amy S.
Soong, Weily
Boguniewicz, Mark
Geng, Bob
Thyssen, Jacob P.
Rosso, Aldana
Steffensen, Louise
Schneider, Shannon
Wollenberg, Andreas
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II46 - II47

← 1 2 3 4 5 →